| Date | Title | Description |
| 02.09.2026 | EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction | PROVIDENCE, R.I., Sept. 3, 2026 /PRNewswire/ -- EpiVax, Inc. is pleased to announce the release of AI-enabled enhancements to ISPRI™, its proprietary in silico platform for assessing the immunogenicity risk of biotherapeutics. The release i... |
| 23.06.2026 | EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services | PROVIDENCE, R.I., June 23, 2026 /PRNewswire/ -- EpiVax, Inc., a recognized leader in immunogenicity risk assessment, announces the expansion of its laboratory facilities at its Providence, RI headquarters. The upgraded space has more than d... |
| 06.04.2026 | Versant Media Group Acquires StockStory | Versant Media Group, Inc. (NASDAQ: VSNT) acquired StockStory, a Middletown, DE-based AI-powered platform delivering financial analysis, market insights, and stock recommendations.
The acquisition enables Versant’s continued expansion of its... |
| 06.04.2026 | EpiVax Receives Investment from SV Health Investors | SV Health Investors, a healthcare and life sciences focused private equity firm, made an investment in EpiVax, Inc., a Providence, RI-based bioanalytical CRO specializing in immunogenicity risk assessments for pharmaceutical and biotech com... |
| 09.12.2025 | EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide | PROVIDENCE, R.I., Dec. 9, 2025 /PRNewswire/ -- EpiVax, Inc., with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators, announces the publication of a study titled "Immunogenicity Risk Assessmen... |
| 30.05.2025 | Navigating Change: EpiVax Welcomes New Leadership Amid Evolving Landscape of Immunogenicity | In the world of biotechnology, change is the only constant. EpiVax, a pioneer in immunogenicity assessment, has embraced this truth with the appointment of Dr. Vibha Jawa as Chief Scientific Officer. This strategic move signals a new chapte... |
| 28.05.2025 | EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO | PROVIDENCE, R.I., May 28, 2025 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity assessment for biologic therapeutics and vaccines, is pleased to announce the appointment of Vibha Jawa, PhD, FAAPS as Chief Scientific Offi... |
| 21.04.2025 | The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies | PROVIDENCE, R.I., April 21, 2025 /PRNewswire/ -- EpiVax, Inc. announces a new study published in Frontiers in Immunology unveiling the impact of peptides known as "Tregitopes" on antibody maturation during immune response.
Lymph n... |
| 27.02.2025 | EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements | PROVIDENCE, R.I., Feb. 27, 2025 /PRNewswire/ -- EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax's immunoinformatics team in 2014 and spearheaded the development of a n... |
| 07.12.2024 | EpiVax Drives Immunogenicity Innovation in 2024: Year in Review | PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification... |
| 24.10.2024 | EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs | PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announce today that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the Office of Generic Dr... |
| 01.04.2024 | Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development | PROVIDENCE, R.I., April 1, 2024 /PRNewswire/ -- In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational tools for predicting and managing immunogenicity risk... |
| 11.08.2023 | Streamlining Generic Drug Immunogenicity Evaluation: EpiVax's "PANDA" Approach | PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ -- EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in ... |
| 17.05.2023 | Providence-based "Biotech start up" EpiVax Celebrates 25th Anniversary | PROVIDENCE, R.I., May 17, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is celebrating its 25th birthday by renewing the company's commitment to improving human health everywhere while highlighting the development of groundbreaking... |
| 10.01.2023 | EpiVax and Zoetis to Collaborate on Swine T cell Epitope Prediction Tool: CircoMatch™ | PROVIDENCE, R.I., Jan. 10, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and Zoetis, are pleased to announce an exclusive collaboration to develop CircoMatch™, a unique bioinformatics tool that predicts the coverage of Porcine Circ... |
| 31.10.2022 | EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine | PROVIDENCE, R.I., Oct. 31, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal v... |
| 13.09.2022 | EpiVax Secures Additional Funding from FDA for Immunogenicity Risk Assessment for Biosimilar Products | PROVIDENCE, R.I., Sept. 13, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce the award of a two-year, $2 million grant from the FDA's Office of Center for Drug Evaluation and Research (CDER) to validate a method... |
| 11.06.2022 | EpiVax Poxvirus Vaccine Candidate Predicted to be Effective Against Monkeypox | PROVIDENCE, R.I., June 11, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces that it has developed VennVax, a smallpox vaccine candidate that is predicted to be highly effective against monkeypox. The development of this vacc... |
| 01.12.2021 | EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants | PROVIDENCE, R.I., Dec. 1, 2021 /PRNewswire/ -- Today EpiVax, Inc. ("EpiVax") confirmed that the company's EPV-CoV-19 vaccine epitopes are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc. ... |
| 04.11.2021 | EpiVax licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition | PROVIDENCE, R.I., Nov. 4, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce an important commercial licensing agreement with Maruho Co., Ltd. ("Maruho") for EpiVax's patented Tregitope technology. This ... |
| 07.07.2021 | Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax | PROVIDENCE, R.I., July 7, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce that Dr. Amy Rosenberg is leaving the FDA's Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as S... |
| 17.05.2021 | EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines | |
| 17.05.2021 | EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines | PROVIDENCE, R.I., May 17, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces the publication "Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation"... |
| 14.05.2021 | Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform | PROVIDENCE, R.I., May 14, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multi–step screening of neoantigens' HLA and TCR–interfaces improves prediction of survival" in Scientific Repor... |
| 13.05.2021 | Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform | |
| 27.04.2021 | EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology | |
| 17.02.2021 | EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO) | |
| 31.12.2020 | EpiVax and EpiVax Therapeutics Advance COVID-19 Vaccine Program, EPV-CoV-19 | |
| 16.04.2020 | Covid-19 vaccine tracker updated to include GSK/Sanofi collaboration | By Jeff Craven
Currently, there are no FDA-approved therapies or vaccines for SARS-CoV-2, the virus that causes Covid-19. The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes... |
| 09.04.2020 | Covid-19 Tracker updates vaccine candidates | By Jeff Craven
On March 11, the World Health Organization classified the Covid-19 outbreak as a pandemic. The disease has reached nearly every country, infecting hundreds of thousands of people and killing thousands.
Curr... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 26.10.2017 | These R.I. Companies Have Won Innovation Vouchers in 2017 – Part Two | Facilitated by the Rhode Island Commerce Corporation, the Innovation Voucher program was created to increase research and development work in the Ocean State.
In its second year, the program provides enterprises employing less than 500 work... |
| 14.09.2016 | EpiVax Wins $600k National Institutes of Health Grant | EpiVax, Inc., a Providence, RI-based immune engineering company, has won a new $600k National Institutes of Health grant.
The grant was awarded under the Small Business Innovation Research (SBIR) program to improve a vaccine for the problem... |
